Dr. Manfred Rotter, University of Vienna, Austria Sponsored by Deb Hand Hygiene www.deb.co.uk





≻In vivo

- Controlled laboratory tests simulating practical conditions on hands of volunteers
- Field trials



SAMPLE SIZE NECESSARY FOR	SIGNIFICA	NT
DIFFERENCE OF PROPO	RTIONS	
(Example for comparativ	trial)	
(Example for comparative	e ti iai)	
PRESENT RATIO OF HAND-TRANSMIT	TED	2 %
NOSOCOMIAL INFECTIONS be		
Desired reduction of infection ratio be	50 %	
NEW RATIO OF HAND-TRANSMITTED		1 %
NOSOCOMIAL INFECTIONS intended be	•	
Level of significance (one-sided)	α= 5 %	
Power of statistical test	$1-\beta = 90\%$	
SAMPLE SIZE		2500
(= Number patients per experimental arm)		
R	otter/teleclass/2005	



Dr. Manfred Rotter, University of Vienna, Austria Sponsored by Deb Hand Hygiene www.deb.co.uk

Bactericidal Properties of Hand Disinfectants Proposed Suspension test prEN 12054

In vitro Test organisms

Temperature Contact time - hygienic - surgical Requirement Staphylococcus aureus Pseudomonas aeruginosa Escherichia coli K 12 Enterococcus hirae 20°C

1 min (optional 0,5 min) 5 min (optional 1,2,3,4 min) reduction: rub 5.0 lg, wash 3.0 lg



Hygienic Handwash with antiseptic soap – EN 1499. Simulating practical Conditions

In vivo	
Volunteers	12-15
Test organism	Escherichia coli K 12
Recovery	Fingertip rub before and after treatment
Application	20
- product	30 or 60 s, according to manufacturer
- reference	60 s handwash with unmedicated soap
Requirement	Product significantly (p = 0.01 unidirectional) more efficacious than soap
Discrimination	Means \geq 0.5 lg different (Power: 0.90)

Simulat	ting practical Conditions
In vivo	
Volunteers	12-15
Test organism	Escherichia coli K 12
Recovery	Fingertip rub before and after treatment
Application:	
- product	30 or 60 s, according to manufacturer
- reference	2 x 30s (=60 s) handrub with 2x3 ml
	60% (vol) 2-propanol
Requirement	Product not significantly (p = 0.1, unidir.) less efficacious than 2-propanol 60%, 1min
Discrimination	Means > 0.6 lg different (Power: 0.95)
	Rotter/CHICA/Desinf, 03 Rotter/teleclass/2005Bo

Hygienic Handrub - EN 1500



DF	Mean Squares	F	Р
4	102,4	327,5	<0,0001
14	2,6	8,1	<0,0001
1	5,8	18,6	<0,0001
42	0,7	2,2	<0,0001
3	3,4	10,8	<0,0001
14	3,1	10,0	<0,0001
42	0.7	2.4	<0.0001
	DF 4 14 1 42 3 14	DF Mean Squares 4 102,4 14 2,6 1 5,8 42 0,7 3 3,4 14 3,1	DF Mean Squares F 4 102,4 327,5 14 2,6 8,1 1 5,8 18,6 42 0,7 2,2 3 3,4 10,8 14 3,1 10,0

Hygionia Hand Disinfaction ANOVA: non standardized

Dr. Manfred Rotter, University of Vienna, Austria Sponsored by Deb Hand Hygiene www.deb.co.uk

ories,	NOVA: RF _{Ri}): 2 laborator h	fection – Al (lg RF _{Pi} ,-lg epetitions , 2 teers in eacl	nd Disin <u>d</u> results nce], 5 r 15 volun	Hygienic Ha <u>standardizer</u> 4 [products–referer with 1
Р	F	Mean SQ	DF	Source of Variation
<0,00001	117,5	90,2	3	Products-Reference (4)
<0,00001	3,5	2,7	14	Volunteers (15)
n.s.	4,6	3,5	1	Laboratories (2)
n.s.	1,1	0,9	42	PxV
n.s.	2,1	1,6	3	VxL
<0,01	2,1	1,7	14	PxL
n.s.	1,2	0,9	42	PxVxL
		0,8	466	Error
-	1,2	0,9 0,8	42 466	PxVxL Error



 Time-kill study (suspension test) with selected strains for 0, 3, 6, 9, 12, 15, 20, 30 min Reservicement



Volunteers (N):	approx. total of 108		
- Test preparation:	approx. 54		
- Positive control:	approx. 54		
 Contaminant bacterium: 	Serratia marcescens , (E	. coli)	
• Contamination and application:	10 times on an experime (Test and control in par	ental day rallel)	
• Samplings:	- after 1st contaminatio - after 1st, 3rd, 7th, 10t	on (baseline) h wash (rub)	
• Required reduction within 5min:	- after 1st handwash:	2 lg	
	- after 10th handwash:	3 lg	
		Rotter/teleclass/2005/Bo	14



			lon rests
Suspension	Tests	In vivo Tests Finger pad	Whole hand
<u>prEN 14476</u>	DVV	ASTM E-1838 (acc. to Sattar)	ASTM E-2011 (Steinmann)
Polio 1	Polio 1	Adeno (human 4)	
Adeno 5	Adeno Vaccinia SV 40	Rota (human) Wa Rhino (human) 37 Hepatitis A HM-1	Rota (human) Rhino (human) 75
4.0 lg	4.0 lg	not defined	not defined



Dr. Manfred Rotter, University of Vienna, Austria Sponsored by Deb Hand Hygiene www.deb.co.uk



In vivo

A Webber Training Teleclass Hosted by Paul Webber paul@webbertraining.com www.webbertraining.com

Rotter//teleclass/2005/Bo

Dr. Manfred Rotter, University of Vienna, Austria Sponsored by Deb Hand Hygiene www.deb.co.uk

Source of Variation	DF	F	р
1 Agents (4)	3	53,97	< 0,001 *
2 Laboratories (5)	4	5,22	< 0,001 *
3 Hands (2)	1	4,93	0,029
1 x 2	12	1,67	0,073
1 x 3	4	1,37	0,249
2 x 3	3	0,66	0,579
1 x 2 x 3	12	1,55	0,107

<u>standardized</u> resu 3 [products –reference], 20 volunte	lts (IgF 5 labo ers in	RF _{Pi} - IgRF pratories, 2 each	_{Ri}): 2 hands,
Source of Variation	DF	F	р
1 [Products-Reference] (3)	2	42,16	< 0,001 *
2 Laboratories (5)	4	1,67	0,162
3 Hands (2)	1	0,70	0,404
1 x 2	8	1,66	0,109
1 x 3	4	3,41	0,012
2 x 3	2	0,63	0,533
1 x 2 x 3	8	0,40	0,918
			Rotter/WHO 2004/B

Surgical Hand Dis	infection: FDA (orig. ASTM E 1115)
Volunteers (N): per arm:	approx: 100 (150)
- Test:	approx. 50
- Positive control:	approx. 50
- (Placebo)	(50)
Testbacteria:	normal resident handflora
Application of Prod	uct:
	acc. to manufacturer's instruction or
	without any: apply product 2 x 5 min, then rinse hands for 1 min
"Baseline":	rinse hands for 30 s, wash hands for 30s,
	rinse hands for 30s
Positive control:	FDA-approved antiseptic; all parameters as product; concurrent testing
	4Rotter Rotter/teleclass/2005

Dr. Manfred Rotter, University of Vienna, Austria Sponsored by Deb Hand Hygiene www.deb.co.uk

Sampling	Dav	of to	est r	erio	de
Times (hrs)	1	2	3	4	5
/60	13bg	8	x	X	8
3	0	8	х	x	0
	<0	Øg	х	х	Glg

bl: Baseline

	Other 2005 Teleclasses For more information, refer to www.webbertraining.com/schedule.cfm
•	<u>April 21</u> – Creutzfeldt-Jakob Disease: Recommendations for Disinfection and Sterilization with Dr. William Rutala
•	<u>April 28</u> – Overcoming the Resistance of Biofilms with Dr. Peter Gilbert Sponsored by Virox Technologies Inc. www.virox.com
•	<u>May 19</u> – Antiseptic Practice & Procedure with Susan Crow Sponsored by 3M Canada www.3m.ca
	May 26 - Canadian Response to West Nile Virus with Dr. Paul Sockett
	June 7 - Measuring the Cost of Hospital Infection with Dr. Barry Cookson
	Questions? Contact Paul Webber paul@webbertraining.com